Sickle Cell Disease study: L-citrulline
Official title Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
ClinicalTrials.gov ID: NCT06635902
What this study is testing
What is L-citrulline?
An investigational intravenous medicine being studied for treating acute pain in sickle cell disease patients.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if IV citrulline shortens the length of pain episodes and to check its safety. It compares citrulline to a placebo.
- Who it's for
- Hospitalized adults with sickle cell disease who are having a vaso‑occlusive pain episode
- What's involved
- Participants receive IV citrulline for 16 hours while in the hospital, then have baseline and follow‑up tests. A placebo group receives a look‑alike substance.
- Time commitment
- The study lasts about one month, including hospital treatment and a clinic visit around 30 days after discharge.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 4 to 21
You may be able to join if
- Sickle cell disease (all genotypes)
- Patients with sickle cell disease ages 4 to 21 years old
- Presence of sickle cell vaso-occlusive pain episode requiring hospitalization and parenteral opioid therapy
- Able to randomize to study drug/placebo within 12 hours of first dose of parenteral opioid in the Emergency Department
You likely can't join if
- Current pain lasting \>3 days.
- \>9 hospitalizations in the prior year
- Presence of any other complication related to sickle cell disease requiring the hospitalization such as splenic sequestration, hepatic sequestration...
- History of opioid use disorder, chronic pain or medical regimen requiring daily opioid use.
- Severe anemia (hemoglobin \<6g/dL)
- Pregnant (as confirmed by a positive urine pregnancy test) or lactating female.
See the full eligibility criteria
- Sickle cell disease (all genotypes)
- Patients with sickle cell disease ages 4 to 21 years old
- Presence of sickle cell vaso-occlusive pain episode requiring hospitalization and parenteral opioid therapy
- Able to randomize to study drug/placebo within 12 hours of first dose of parenteral opioid in the Emergency Department
- Current pain lasting \>3 days.
- \>9 hospitalizations in the prior year
- Presence of any other complication related to sickle cell disease requiring the hospitalization such as splenic sequestration, hepatic sequestration, stroke, transient ischemic attack, etc.
- History of opioid use disorder, chronic pain or medical regimen requiring daily opioid use.
- Severe anemia (hemoglobin \<6g/dL)
- Pregnant (as confirmed by a positive urine pregnancy test) or lactating female.
- Alanine/aspartate transferase \>2x upper limit of normal laboratory range for age.
- Age 4 to 13 years \> 0.9 mg/dL
- Age 14 to 17 years 1.0 mg/dL
- Age ≥18 years \>1.5mg/dL
- Presence of acute chest syndrome, sepsis, bacterial infection, hemodynamic instability
- Use of L-glutamine
- History of allergic reaction to L-citrulline products
The study team makes the final eligibility decision.
Where it is enrolling
- Washington D.C., District of Columbia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 4 years to 21 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Washington D.C., District of Columbia, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.